Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's Neurocrine Biosciences Second Quarter 2025 Results Conference.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 2,366,397 | $297,432,439 | -6% | 0.4% |
| 2. | Citadel Investment Group Ken Griffin | 2,049,075 | $257,548,237 | +131% | 0.04% |
| 3. | AQR Capital Management Cliff Asness | 1,510,015 | $189,793,729 | +41% | 0.16% |
| 4. | Millennium Management Israel Englander | 1,194,219 | $150,101,386 | +108% | 0.07% |
| 5. | Deerfield Management James E. Flynn | 1,167,802 | $146,781,033 | -22% | 2.66% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | $132,796.50 | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | $5,955.00 | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | $36,921.00 | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | $21,768.30 | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | $249,779.13 | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $126.41 | 106,322 | $13,440,280.97 | 514,596 | 2025-08-07 | Filing | |
| $135.00 | 457 | $61,695.00 | 4,730 | 2025-07-10 | Filing | |
| $130.46 | 59,819 | $7,803,687.65 | 18,289 | 2025-07-09 | Filing | |
| $130.13 | 20,362 | $2,649,737.60 | 18,289 | 2025-07-02 | Filing | |
| $120.38 | 9,613 | $1,157,211.02 | 514,596 | 2025-05-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,954,765 | $1,628,284,415 | 0.03% | |
| 2. | 9,807,066 | $1,232,650,125 | 0.02% | |
| 3. | 5,566,814 | $699,692,852 | 0.39% | |
| 4. | 4,468,266 | $561,616,354 | 0.02% | |
| 5. | 4,261,747 | $535,659,088 | 0.04% |
News See All
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders.
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan Stanley raised the firm’s price target on Neurocrine Biosciences, Inc.
10 Best Strong Buy Healthcare Stocks to Buy Now
On July 21, Jared Holz, Mizuho health care sector strategist, appeared on CNBC's 'The Exchange' to talk about whether any opportunity plays exist within the healthcare sector, and what pains the sector...
11 Best Long Term Low Risk Stocks to Invest in
The uncertainty prevailing in the current market environment demands a closer examination beyond just earnings reports and share price trends when seeking a worthy investment.
Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the 11 best debt-free stocks to invest in right now.
11 Best Debt-Free Stocks to Invest in Right Now
It is widely understood that employing debt to fund operations can act as a powerful financial tool. But debt doesn't come without its trade-offs.
Guggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor Meeting
On June 4, analysts at Guggenheim reiterated their Buy rating for Neurocrine Biosciences, Inc. (NASDAQ:NBIX), keeping their price target at $165.
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying
The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two years of weak performance, the healthcare sector kicked off on a strong note in 2025.
Billionaire Hedge Funds
